Back to Search Start Over

Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11

Authors :
Laura, Andreoli
Cecilia B, Chighizola
Luca, Iaccarino
Angela, Botta
Maria, Gerosa
Véronique, Ramoni
Chiara, Tani
Bonnie, Bermas
Antonio, Brucato
Jill, Buyon
Irene, Cetin
Christina D, Chambers
Megan E B, Clowse
Nathalie, Costedoat-Chalumeau
Maurizio, Cutolo
Sara, De Carolis
Radboud, Dolhain
Elisa M, Fazzi
Frauke, Förger
Ian, Giles
Isabell, Haase
Munther, Khamashta
Roger A, Levy
Pier Luigi, Meroni
Marta, Mosca
Catherine, Nelson-Piercy
Luigi, Raio
Jane, Salmon
Peter, Villiger
Marie, Wahren-Herlenius
Marianne, Wallenius
Cristina, Zanardini
Yehuda, Shoenfeld
Angela, Tincani
Source :
Autoimmunity reviews. 22(3)
Publication Year :
2022

Abstract

Autoimmune rheumatic diseases (ARD) can affect women and men during fertile age, therefore reproductive health is a priority issue in rheumatology. Many topics need to be considered during preconception counselling: fertility, the impact of disease-related factors on pregnancy outcomes, the influence of pregnancy on disease activity, the compatibility of medications with pregnancy and breastfeeding. Risk stratification and individualized treatment approach elaborated by a multidisciplinary team minimize the risk of adverse pregnancy outcomes (APO). Research has been focused on identifying biomarkers that can be predictive of APO. Specifically, preeclampsia and hypertensive disorders of pregnancy tend to develop more frequently in women with ARD. Placental insufficiency can lead to intrauterine growth restriction and small-for-gestational age newborns. Such APO have been shown to be associated with maternal disease activity in different ARD. Therefore, a key message to be addressed to the woman wishing for a pregnancy and to her family is that treatment with compatible drugs is the best way to ensure maternal and fetal wellbeing. An increasing number of medications have entered the management of ARD, but data about their use in pregnancy and lactation are scarce. More information is needed for most biologic drugs and their biosimilars, and for the so-called small molecules, while there is sufficient evidence to recommend the use of TNF inhibitors if needed for keeping maternal disease under control. Other issues related to the reproductive journey have emerged as "unmet needs", such as sexual dysfunction, contraception, medically assisted reproduction techniques, long-term outcome of children, and they will be addressed in this review paper. Collaborative research has been instrumental to reach current knowledge and the future will bring novel insights thanks to pregnancy registries and prospective studies that have been established in several Countries and to their joint efforts in merging data.

Details

ISSN :
18730183
Volume :
22
Issue :
3
Database :
OpenAIRE
Journal :
Autoimmunity reviews
Accession number :
edsair.pmid..........2a9f1bc6f6bddb41f206035c6acd466a